PRME
Prime Medicine, Inc.
$2.96
-3.27%
$534.6M
No data for this timeframe.
Vol
Market Cap$534.6M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (74%)
Inst. Holders8 funds
Inst. Value$50.2M
Inst. Activity6 buys / 0 sells
SEC Reports3
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001894562·Prev Close $3.06
Recent Activity
Jun 9, 2026
short_volume
Short Volume: PRME — 61.3% short (0.7M / 1.2M)
Short: 723,295 | Exempt: 8,525 | TRF Vol: 1,179,841 | Short Ratio: 61.3% | Off-exchange volume (dark
Jun 5, 2026
Insider
Schenkein David P sold 75,000 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
NELSEN ROBERT sold 75,000 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
Kelly Michael Aaron sold 75,000 shares
Director @ $0.00 ($0.00)
May 7, 2026
SEC
Prime Medicine reported Q1 2026 EPS of -$0.28, missing consensus of -$0.24 by 16.7%, and revenue of $856K, down 41% YoY.
8-K — Impact 6/10
May 7, 2026
SEC
Prime Medicine reported Q1 2026 EPS of -$0.28, missing consensus of -$0.25 by 12%, and collaboration revenue of $856K ve
PRESS-RELEASE — Impact 5/10
Apr 16, 2026
SEC
Prime Medicine appointed Svetlana Makhni as CFO effective April 16, 2026, with a $495,000 base salary, 40% bonus target,
8-K — Impact 3/10
Inst.
VANGUARD GROUP INC — ADD
6,467,872 shares ($22.4M)
Price Targets
$6.92
+140.2% upside
Strong Buy
Current $2.88
Low $4.25
Median $6.00
High $11.00
9 analysts
$4.25
$11.00
Analyst Ratings
6Strong Buy
8Buy
5Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 12, 2026 | Oppenheimer | INITIATE | Outperform |
| Dec 23, 2025 | LifeSci Capital | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.25 ▼ -10.0% | $-0.29 — $-0.18 | 39% YoY | 11 |
| Next Q | $-0.23 ▲ +2.9% | $-0.31 — $-0.02 | 28% YoY | 11 |
| Current FY | $-0.98 ▼ -7.2% | $-1.18 — $-0.77 | 28% YoY | 11 |
| Next FY | $-0.87 ▼ -9.4% | $-1.40 — $-0.41 | 11% YoY | 9 |
Latest Reports
BEARISH
8-K
6/10
Prime Medicine reported Q1 2026 EPS of -$0.28, missing consensus of -$0.24 by 16.7%, and revenue of $856K, down 41% YoY.
May 7, 2026
BEARISH
PRESS-RELEASE
5/10
Prime Medicine reported Q1 2026 EPS of -$0.28, missing consensus of -$0.25 by 12%, and collaboration revenue of $856K ve
May 7, 2026
MIXED
Press
6/10
Prime Medicine reported its full-year 2025 financial results and provided a business update, highlighting progress in it
Mar 3, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $22.4M | ADD |
| FMR LLC | $7.6M | — |
| TWO SIGMA INVESTMENTS, LP | $5.7M | DOUBLED |
| MORGAN STANLEY | $4.1M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $4.0M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Schenkein David | A | $0.00 |
| Jun 5, 2026 | NELSEN ROBERT | A | $0.00 |
| Jun 5, 2026 | Kelly Michael | A | $0.00 |
| Jun 5, 2026 | Foster-Cheek Kaye | A | $0.00 |
| Jun 5, 2026 | Chung Wendy | A | $0.00 |
8 institutional holders with $50.2M total value (14,472,222 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, TWO. Net buying activity: 6 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 6,467,872 | $22.4M | 44.7% | ADD +31.4% |
| 2 | FMR LLC | 2,176,646 | $7.6M | 15.0% | — |
| 3 | TWO SIGMA INVESTMENTS, LP | 1,629,324 | $5.7M | 11.3% | DOUBLED +264.0% |
| 4 | MORGAN STANLEY | 1,169,898 | $4.1M | 8.1% | ADD +60.0% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 1,149,159 | $4.0M | 7.9% | DOUBLED +407.9% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 936,815 | $3.3M | 6.5% | ADD +63.4% |
| 7 | BANK OF AMERICA CORP /DE/ | 648,012 | $2.2M | 4.5% | DOUBLED +484.6% |
| 8 | WELLS FARGO & COMPANY/MN | 294,496 | $1.0M | 2.0% | ADD +49.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 4,921,865 | 6,467,872 | +31.4% | $22.4M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 447,667 | 1,629,324 | +264.0% | $5.7M | 2025-Q4 |
| MORGAN STANLEY | ADD | 731,004 | 1,169,898 | +60.0% | $4.1M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 573,158 | 936,815 | +63.4% | $3.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 110,842 | 648,012 | +484.6% | $2.2M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 197,014 | 294,496 | +49.5% | $1.0M | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 3,627,510 | 4,921,865 | +35.7% | $27.3M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 223,400 | 1,134,670 | +407.9% | $6.3M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 258,423 | 447,667 | +73.2% | $2.5M | 2025-Q3 |
| UBS Group AG | ADD | 195,327 | 304,773 | +56.0% | $1.7M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 101,151 | 197,014 | +94.8% | $1.1M | 2025-Q3 |
| MORGAN STANLEY | ADD | 355,176 | 587,676 | +65.5% | $1.5M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 447,600 | 223,400 | -50.1% | $551.8K | 2025-Q2 |
| UBS Group AG | ADD | 117,680 | 195,327 | +66.0% | $482.5K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 112,926 | 144,511 | +28.0% | $356.9K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 447,600 | — | $890.7K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 166,199 | 258,770 | +55.7% | $515.0K | 2025-Q1 |
| UBS Group AG | TRIM | 218,186 | 117,680 | -46.1% | $234.2K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 138,400 | 88,300 | -36.2% | $175.7K | 2025-Q1 |
| UBS Group AG | DOUBLED | 35,021 | 218,186 | +523.0% | $637.1K | 2024-Q4 |
| CITADEL ADVISORS LLC | ADD | 105,595 | 138,400 | +31.1% | $404.1K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 171,468 | 96,181 | -43.9% | $280.8K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 20,000 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 463,977 | — | $1.8M | 2024-Q3 |
| MORGAN STANLEY | ADD | 183,965 | 300,391 | +63.3% | $1.2M | 2024-Q3 |
10 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Schenkein David P | Director | A | 75,000 | $0.00 | $0.00 |
| Jun 5, 2026 | NELSEN ROBERT | Director | A | 75,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Kelly Michael Aaron | Director | A | 75,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Foster-Cheek Kaye I | Director | A | 75,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Chung Wendy | Director | A | 75,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Cahill Thomas | Director | A | 75,000 | $0.00 | $0.00 |
| Apr 16, 2026 | Makhni Svetlana Ni | Chief Financial Officer | A | 800,000 | $0.00 | $0.00 |
| Feb 26, 2026 | Reine Allan | Chief Executive Officer | A | 1,300,000 | $0.00 | $0.00 |
| Feb 23, 2026 | LEE ANN L. | Chief Technical Officer | A | 375,000 | $0.00 | $0.00 |
| Feb 23, 2026 | Alenson Carman | See Remarks | A | 140,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 4.7/10.
BEARISH
8-K
6/10
Prime Medicine reported Q1 2026 EPS of -$0.28, missing consensus of -$0.24 by 16.7%, and revenue of
May 7, 2026
BEARISH
PRESS-RELEASE
5/10
Prime Medicine reported Q1 2026 EPS of -$0.28, missing consensus of -$0.25 by 12%, and collaboration
May 7, 2026
NEUTRAL
8-K
3/10
Prime Medicine appointed Svetlana Makhni as CFO effective April 16, 2026, with a $495,000 base salar
Apr 16, 2026
Current analyst consensus: Buy (74% buy). Based on 19 analysts: 6 strong buy, 8 buy, 5 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.92 mean target
+140.2% upside
Strong Buy (3.00)
$4.25 Low
$11.00 High
| Metric | Value |
|---|---|
| Current Price | $2.88 |
| Target Low | $4.25 |
| Target Mean | $6.92 |
| Target Median | $6.00 |
| Target High | $11.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.25 | $-0.29 | $-0.18 | 38.9% | -10.0% | 1↑ 4↓ | $0.0B | 88.8% | 11 |
| Next Q 2026-09-30 |
$-0.23 | $-0.31 | $-0.02 | 28.3% | +2.9% | 2↑ 3↓ | $0.0B | 470.4% | 11 |
| Current FY 2026-12-31 |
$-0.98 | $-1.18 | $-0.77 | 27.5% | -7.2% | 1↑ 6↓ | $0.0B | 179.1% | 11 |
| Next FY 2027-12-31 |
$-0.87 | $-1.40 | $-0.41 | 10.9% | -9.4% | 4↑ 2↓ | $0.0B | 74.2% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.251 | |
| 7d ago | $-0.228 | -0.023 |
| 30d ago | $-0.228 | -0.023 |
| 60d ago | $-0.227 | -0.024 |
| 90d ago | $-0.242 | -0.009 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 12, 2026 | Oppenheimer | INITIATE | — | Outperform |
| Dec 23, 2025 | LifeSci Capital | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 8 | 5 | 0 | 0 | 74% | |
| May 1, 2026 | 6 | 8 | 5 | 0 | 0 | 74% | |
| Apr 1, 2026 | 6 | 8 | 5 | 0 | 0 | 74% | |
| Mar 1, 2026 | 5 | 7 | 5 | 0 | 0 | 71% | |
| Feb 1, 2026 | 5 | 7 | 5 | 0 | 0 | 71% | |
| Jan 1, 2026 | 5 | 7 | 5 | 0 | 0 | 71% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
short_volume
Short Volume: PRME — 61.3% short (0.7M / 1.2M)
Short: 723,295 | Exempt: 8,525 | TRF Vol: 1,179,841 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: PRME — 66.4% short (0.8M / 1.2M)
Short: 811,454 | Exempt: 42,924 | TRF Vol: 1,221,880 | Short Ratio: 66.4% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: PRME — 72.2% short (1.9M / 2.6M)
Short: 1,864,045 | Exempt: 60,128 | TRF Vol: 2,582,695 | Short Ratio: 72.2% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: PRME — 72.5% short (1.3M / 1.8M)
Short: 1,286,391 | Exempt: 15,888 | TRF Vol: 1,774,588 | Short Ratio: 72.5% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: PRME — 63.9% short (0.7M / 1.0M)
Short: 656,775 | Exempt: 674 | TRF Vol: 1,027,380 | Short Ratio: 63.9% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: PRME — 55.0% short (0.5M / 0.9M)
Short: 499,544 | Exempt: 6,784 | TRF Vol: 908,240 | Short Ratio: 55.0% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: PRME — 73.3% short (0.6M / 0.9M)
Short: 628,497 | Exempt: 15 | TRF Vol: 857,299 | Short Ratio: 73.3% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: PRME — 60.5% short (0.4M / 0.7M)
Short: 402,867 | Exempt: 55 | TRF Vol: 666,244 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: PRME — 71.3% short (0.6M / 0.8M)
Short: 598,460 | Exempt: 1,500 | TRF Vol: 839,174 | Short Ratio: 71.3% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: PRME — 61.8% short (0.5M / 0.8M)
Short: 507,558 | Exempt: 4,688 | TRF Vol: 821,083 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: PRME — 65.6% short (1.0M / 1.6M)
Short: 1,040,576 | Exempt: 28,732 | TRF Vol: 1,585,218 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: PRME — 66.6% short (0.9M / 1.4M)
Short: 905,367 | Exempt: 2,134 | TRF Vol: 1,359,119 | Short Ratio: 66.6% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: PRME — 70.4% short (0.8M / 1.1M)
Short: 796,919 | Exempt: 1,378 | TRF Vol: 1,132,056 | Short Ratio: 70.4% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: PRME — 61.1% short (0.6M / 1.0M)
Short: 586,432 | Exempt: 1,626 | TRF Vol: 959,402 | Short Ratio: 61.1% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: PRME — 69.4% short (0.9M / 1.3M)
Short: 882,208 | Exempt: 0 | TRF Vol: 1,271,609 | Short Ratio: 69.4% | Off-exchange volume (dark pool + OTC)